2024
Factors influencing adverse events following COVID-19 vaccination
Villanueva P, McDonald E, Croda J, Croda M, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Lynn D, Marshall H, Oliveira R, Rocha J, Sawka A, Val F, Pittet L, Messina N, Curtis N. Factors influencing adverse events following COVID-19 vaccination. Human Vaccines & Immunotherapeutics 2024, 20: 2323853. PMID: 38445666, PMCID: PMC10936640, DOI: 10.1080/21645515.2024.2323853.Peer-Reviewed Original ResearchMeSH KeywordsBNT162 VaccineChAdOx1 nCoV-19Cohort StudiesCOVID-19COVID-19 VaccinesFemaleHumansVaccinationConceptsVaccine typesSystemic reactionsIncidence of AEFIAdverse eventsVaccine doseIncidence of adverse eventsCovid-19 specific vaccineCOVID-19 vaccineNested cohort studyIgG antibody responsesRisk of AEFICOVID-19 vaccine typesChAdOx1 recipientsBNT162b2 recipientsCohort studyPfizer-BioNTechCoronaVac vaccineAntibody responseChAdOx1Oxford-AstraZenecaCoronaVacBNT162b2Local reactionsDoseDevelopment of COVID-19 vaccines
2023
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
Messina N, Sperotto M, Puga M, da Silva P, de Oliveira R, Moore C, Pittet L, Jamieson T, Dalcolmo M, dos Santos G, Jardim B, Lacerda M, Curtis N, Croda J. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination. Frontiers In Immunology 2023, 14: 1172851. PMID: 37465688, PMCID: PMC10352084, DOI: 10.3389/fimmu.2023.1172851.Peer-Reviewed Original ResearchMeSH KeywordsAntibody FormationBCG VaccineChAdOx1 nCoV-19COVID-19COVID-19 VaccinesHumansImmunoglobulin GVaccinationConceptsRecent BCG vaccinationBCG vaccinationAntibody responseVaccine platformAnti-spike IgG responseCOVID-19 vaccinationCOVID-19 vaccineCoronaVac vaccinationPrior vaccinationVaccine responsesIgG responsesSecond doseIgG antibodiesHealthcare workersVaccinationChAdOx1CoronaVacCOVID-19VaccineMultiple factorsResponsePlaceboDoseTrialsAntibodiesExploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges
Croda J. Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges. The Lancet Infectious Diseases 2023, 23: 1099-1100. PMID: 37352881, PMCID: PMC10281640, DOI: 10.1016/s1473-3099(23)00363-8.Peer-Reviewed Original ResearchRandomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers
Pittet L, Messina N, Orsini F, Moore C, Abruzzo V, Barry S, Bonnici R, Bonten M, Campbell J, Croda J, Dalcolmo M, Gardiner K, Gell G, Germano S, Gomes-Silva A, Goodall C, Gwee A, Jamieson T, Jardim B, Kollman T, Lacerda M, Lee K, Lucas M, Lynn D, Manning L, Marshall H, McDonald E, Munns C, Nicholson S, O’Connell A, de Oliveira R, Perlen S, Perrett K, Prat-Aymerich C, Richmond P, Rodriguez-Baño J, dos Santos G, da Silva P, Teo J, Villanueva P, Warris A, Wood N, Davidson A, Curtis N. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. New England Journal Of Medicine 2023, 388: 1582-1596. PMID: 37099341, PMCID: PMC10497190, DOI: 10.1056/nejmoa2212616.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicBCG VaccineCOVID-19COVID-19 VaccinesDouble-Blind MethodHealth PersonnelHumansSARS-CoV-2ConceptsBacille Calmette-GuerinModified intention-to-treat populationIntention-to-treat populationSevere COVID-19Placebo groupSymptomatic COVID-19Health care workersBCG-DenmarkPlacebo-controlled trialCare workersRisk of severe COVID-19Double-blindSaline placeboRisk of symptomatic COVID-19Severe acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Negative testRandomized trialsRespiratory syndrome coronavirus 2Hazard ratioPrimary outcomeBCG vaccinationTrial definitionSyndrome coronavirus 2Risk difference
2022
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes CFR, Lind ML, Torres MSS, Tsuha DH, David LCS, Said RFC, Almiron M, de Oliveira RD, Cummings DAT, Dean NE, Andrews JR, Ko AI, Croda J. Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature Communications 2022, 13: 5536. PMID: 36202800, PMCID: PMC9537178, DOI: 10.1038/s41467-022-33169-0.Peer-Reviewed Original ResearchMeSH KeywordsAdultBNT162 VaccineBrazilCase-Control StudiesCOVID-19COVID-19 VaccinesHumansVaccines, Inactivated
2021
Booster doses for inactivated COVID-19 vaccines: if, when, and for whom
Croda J, Ranzani O. Booster doses for inactivated COVID-19 vaccines: if, when, and for whom. The Lancet Infectious Diseases 2021, 22: 430-432. PMID: 34890538, PMCID: PMC8651253, DOI: 10.1016/s1473-3099(21)00696-4.Peer-Reviewed Original Research